Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the initiation management predischarge: Process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial

Wendy A. Gattis, Christopher M. O'Connor, Dianne S. Gallup, Vic Hasselblad, Mihai Gheorghiade*

*Corresponding author for this work

Research output: Contribution to journalArticle

254 Scopus citations

Abstract

Objectives The Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial was an investigator-initiated study to evaluate if predischarge carvedilol initiation in stabilized patients hospitalized for heart failure (HF) increased the number of patients treated with beta-blockade at 60 days after randomization without increasing side effects or length of hospital stay. Background Beta-blockers are underused in HF. Predischarge initiation may improve the use of evidence-based beta-blockade. Methods The IMPACT-HF was a prospective, randomized open-label trial conducted in 363 patients hospitalized for HF. Patients were randomized to carvedilol initiation pre-hospital discharge or to postdischarge initiation (>2 weeks) of beta-blockade at the physicians' discretion. The primary end point of the study was the number of patients treated with beta-blockade at 60 days after randomization. Secondary end points included the number of patients discontinuing beta-blockade, median dose achieved, and a composite of death, rehospitalization, unscheduled visit for HF, or ≥50% increase in oral diuretic, new oral diuretic, or any intravenous therapy with diuretics, inotropes, or other vasoactive agents. Results At 60 days 165 patients (91.2%) randomized to predischarge carvedilol initiation were treated with a beta-blocker, compared with 130 patients (73.4%) randomized to initiation postdischarge (p < 0.0001). Predischarge initiation was not associated with an increased risk of serious adverse events. The median length of stay was five days in both groups. Conclusions Predischarge initiation of carvedilol in stabilized patients hospitalized for HF improved the use of beta-blockade at 60 days without increasing side effects or length of stay. Predischarge initiation may be one approach to improve beta-blocker use in this population.

Original languageEnglish (US)
Pages (from-to)1534-1541
Number of pages8
JournalJournal of the American College of Cardiology
Volume43
Issue number9
DOIs
StatePublished - May 5 2004

Keywords

  • ADHERE
  • Acute Decompensated Heart Failure National Registry
  • DCRI
  • DSMB
  • Data Safety Monitoring Board
  • Duke Clinical Research Institute
  • HF
  • HFSA
  • Heart Failure Society of America
  • IMPACT-HF
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the initiation management predischarge: Process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial'. Together they form a unique fingerprint.

  • Cite this